What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing prevalence.

What are the key drivers of the Drugs for Treating Hyperuricemia market?

Key drivers include rising awareness, growing geriatric population, and increasing healthcare expenditure.

What are the major challenges facing the market?

Challenges include high treatment costs, limited awareness in developing regions, and side effects.

Which regions are leading the Drugs for Treating Hyperuricemia market?

North America and Europe are leading regions, due to high healthcare expenditure and awareness.

Who are the top companies in the Drugs for Treating Hyperuricemia market?

Top companies include AstraZeneca, GlaxoSmithKline, and Pfizer, offering innovative treatments.

What future opportunities exist in the market?

Future opportunities include emerging markets, novel therapies, and increasing demand for combination treatments.

How is technology impacting the Drugs for Treating Hyperuricemia market?

Technology is driving personalized medicine, improving diagnosis, and enhancing treatment outcomes.

What is the current regulatory landscape for the market?

The regulatory landscape is evolving, with increasing focus on safety, efficacy, and patient-centricity.

What is the future outlook for the Drugs for Treating Hyperuricemia market?

The future outlook is positive, with growing demand, innovative treatments, and increasing investment.

Drugs for Treating Hyperuricemia Market Intelligence Report 2026 — Updated June 2026

Drugs for Treating Hyperuricemia by Application (Hospitals and Clinics, Retail Pharmacies, Other), by Types (Uric Acid Production Inhibitors, Urate-stimulating Excretion Agents, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Drugs for Treating Hyperuricemia Market Size | CAGR 6.8 Forecast 2033

Drugs for Treating Hyperuricemia Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Drugs for Treating Hyperuricemia Market Overview

The Drugs for Treating Hyperuricemia market refers to the industry that focuses on developing and marketing medications for managing hyperuricemia, a condition characterized by elevated levels of uric acid in the blood. As the prevalence of hyperuricemia and related disorders such as gout continues to rise, the Drugs for Treating Hyperuricemia market size is anticipated to experience significant growth. The growth outlook for this market is promising, with a projected market forecast that indicates substantial expansion during the forecast period. Key drivers of industry expansion include increasing awareness about hyperuricemia, advancements in treatment options, and growing demand for effective therapies. The current Drugs for Treating Hyperuricemia market size is approximately $1.4 billion, with an expected compound annual growth rate (CAGR) of 6.5% from 2026 to 2033.

Loading chart…

Several key forces are shaping the Drugs for Treating Hyperuricemia industry, including technology shifts towards more targeted therapies, regulations that encourage innovation, and changing consumer behavior that prioritizes effective and safe treatments. The largest region for this market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare spending and a rising awareness of hyperuricemia. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest developments and trends in the Drugs for Treating Hyperuricemia market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	20.90 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Mylan Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Sanwa Kagaku Kenkyusho Co., Ltd.; Towa Pharmaceutical Co., Ltd.; Toa Eiyo Co., Ltd.; AstraZeneca PLC; Mochida Pharmaceutical Co., Ltd.; Lannett Company, Inc.; Horizon Therapeutics plc; Sanofi S.A.; GlaxoSmithKline plc; Fuji Yakuhin Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Drugs for Treating Hyperuricemia market is experiencing significant growth, driven by various factors. The market dynamics are shaped by several key elements, including growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Increasing prevalence of hyperuricemia and related disorders, such as gout, is driving the demand for effective treatments, thereby contributing to the growth of the Drugs for Treating Hyperuricemia market size.

Advances in medical technology and pharmaceutical research are leading to the development of innovative and more effective treatments, which is expected to boost the growth forecast of the Drugs for Treating Hyperuricemia market.

Restraints2 items

High development costs and strict regulatory requirements are limiting the entry of new players in the Drugs for Treating Hyperuricemia market, thereby restraining its growth.

Increasing competition from generic drugs and alternative therapies is also expected to hinder the growth of the Drugs for Treating Hyperuricemia market size in the coming years.

Opportunities2 items

The growing awareness about hyperuricemia and its treatments is creating new opportunities for market players to develop and market effective drugs, driving the growth forecast of the Drugs for Treating Hyperuricemia market.

The increasing demand for personalized medicine and targeted therapies is also expected to provide opportunities for market players to develop innovative treatments and expand their presence in the Drugs for Treating Hyperuricemia market.

Challenges2 items

The Drugs for Treating Hyperuricemia market is facing challenges due to the patent expiration of key drugs, which is expected to lead to a decline in revenue and market share for some players.

The pricing pressure and reimbursement issues are also expected to challenge the growth of the Drugs for Treating Hyperuricemia market, as market players may struggle to maintain profitability and access to their drugs.

Market Segmentation

Loading chart…

The Application segment of the Drugs for Treating Hyperuricemia market refers to the various uses of these drugs in treating different conditions associated with hyperuricemia. This includes gout, which is a form of inflammatory arthritis characterized by sudden, severe attacks of pain, swelling, redness, and tenderness. The application segment is crucial in understanding the Drugs for Treating Hyperuricemia segmentation, as it helps in identifying the specific areas where these drugs are most effective, thereby contributing to the overall market size.

The Types segment of the Drugs for Treating Hyperuricemia market encompasses various subtypes of drugs used to treat hyperuricemia, including [object Object] and [object Object]. This segment is vital in the market taxonomy, as it enables the analysis of the different classes of drugs available for treating hyperuricemia, such as xanthine oxidase inhibitors, uricosurics, and corticosteroids. By examining the types of drugs used, researchers can gain insight into the treatment preferences of patients and physicians, ultimately influencing the Drugs for Treating Hyperuricemia market size.

Drugs for Treating Hyperuricemia Segmentation Breakdown8 items

Application

Hospitals and Clinics

Retail Pharmacies

Other

Types

Uric Acid Production Inhibitors

Urate-stimulating Excretion Agents

Other

Regional Insights

Loading chart…

The Drugs for Treating Hyperuricemia market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 35% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of novel therapies and rising demographics with hyperuricemia.

Key drivers for each region include: for North America, policies supporting research and development, significant investments in healthcare infrastructure, and a mature ecosystem for pharmaceuticals. In Europe, factors such as adoption of innovative treatments, favorable policies for drug development, and a strong infrastructure for clinical trials are expected to influence the market. Asia Pacific's growth will be fueled by a large and growing demographics, increasing adoption of modern healthcare practices, and strategic investments in the pharmaceutical sector. Latin America and Middle East & Africa will see growth due to improving infrastructure, expanding ecosystem maturity, and rising adoption of treatments for hyperuricemia.

The regional forecast indicates that the Drugs for Treating Hyperuricemia market will experience significant growth, driven by these regional factors. Understanding these dynamics is crucial for market players to capitalize on emerging opportunities and navigate challenges in each region.

Competitive Landscape

The Drugs for Treating Hyperuricemia market is moderately consolidated, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Drugs for Treating Hyperuricemia competitive landscape is driven by the need for companies to differentiate themselves through strategic partnerships, innovative product portfolios, and strong distribution networks. Key competitive levers include pricing strategies, distribution channels, and product innovation, with companies focusing on developing new treatments and improving existing ones to gain a competitive edge.

Companies in the market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To overcome these challenges, companies are focusing on strategic initiatives such as regional expansion, innovation pipeline, and local manufacturing. The following companies are implementing these strategies:

Teva Pharmaceutical Industries Ltd. - regional expansion

Mylan Pharmaceuticals Inc. - vertical integration

Takeda Pharmaceutical Company Limited - premium pricing

Sanwa Kagaku Kenkyusho Co., Ltd. - OEM tie-ups

Towa Pharmaceutical Co., Ltd. - innovation pipeline

Toa Eiyo Co., Ltd. - local manufacturing

Key Drugs for Treating Hyperuricemia Companies13 items

Teva Pharmaceutical Industries Ltd.

Mylan Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited

Sanwa Kagaku Kenkyusho Co., Ltd.

Towa Pharmaceutical Co., Ltd.

Toa Eiyo Co., Ltd.

AstraZeneca PLC

Mochida Pharmaceutical Co., Ltd.

Lannett Company, Inc.

Horizon Therapeutics plc

Sanofi S.A.

GlaxoSmithKline plc

Fuji Yakuhin Co., Ltd.

Market Ecosystem

The Drugs for Treating Hyperuricemia ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream activities. This ecosystem is characterized by a series of interactions between technology providers, integrators, channels, and end users, ultimately creating and capturing value through the development, production, and distribution of hyperuricemia treatments. A comprehensive value chain analysis is essential to understanding the intricacies of this ecosystem and identifying key areas of influence.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing finished drugs

Technology providers — developing novel therapeutic approaches

Distributors / channel partners — delivering products to healthcare providers

Service providers / after-sales — offering patient support and education

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — patients and healthcare professionals

Within the Drugs for Treating Hyperuricemia ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the approval and adoption of new treatments. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and standards, including those related to manufacturing and labeling. Switching costs and partnerships are also critical, as they can impact the interoperability of different treatments and the willingness of healthcare providers to adopt new therapies. Furthermore, the ecosystem differs by region, with varying regulatory requirements, reimbursement policies, and patient needs, highlighting the importance of a nuanced understanding of these factors to navigate the complex landscape of the Drugs for Treating Hyperuricemia ecosystem.

Recent Industry Insights

The Drugs for Treating Hyperuricemia industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between major pharmaceutical companies, have focused on developing innovative treatments for hyperuricemia. Additionally, there have been notable mergers and acquisitions, with companies expanding their portfolios to include novel therapies. Several product launches have also taken place, introducing new medications that offer improved efficacy and safety profiles. Regulatory changes have further shaped the industry, with updates to treatment guidelines and the approval of new therapies.

Furthermore, the industry has seen a shift in consumer trends, with an increasing emphasis on preventative care and lifestyle modifications to manage hyperuricemia. Funding rounds have also been secured by emerging companies, enabling them to advance their research and development programs. These developments are expected to drive growth in the Drugs for Treating Hyperuricemia market, as the industry continues to evolve in response to changing patient needs and technological advancements.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Drugs for Treating Hyperuricemia market outlook. The market attractiveness is moderate, driven by an increasing prevalence of hyperuricemia and a growing demand for effective treatments. The competitive intensity is high, with several key players competing for market share. The long-term outlook is positive, with opportunities for innovation and growth in emerging markets. The innovation landscape is evolving, with a focus on developing more effective and targeted therapies. However, the demand-supply balance is a key concern, with potential risks related to supply chain disruptions and regulatory changes. Key risk factors include intense competition, regulatory hurdles, and patent expirations.

12 items

1. Executive Summary

2. Drugs for Treating Hyperuricemia Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drugs for Treating Hyperuricemia Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Drugs for Treating Hyperuricemia Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Drugs for Treating Hyperuricemia Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Drugs for Treating Hyperuricemia Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Drugs for Treating Hyperuricemia Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Drugs for Treating Hyperuricemia Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Drugs for Treating Hyperuricemia Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Drugs for Treating Hyperuricemia Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Drugs for Treating Hyperuricemia Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Drugs for Treating Hyperuricemia Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drugs for Treating Hyperuricemia Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Drugs for Treating Hyperuricemia Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Drugs for Treating Hyperuricemia Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Drugs for Treating Hyperuricemia Market Competition by Key Manufacturers

9.1. Global Drugs for Treating Hyperuricemia Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Drugs for Treating Hyperuricemia: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Teva Pharmaceutical Industries Ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Mylan Pharmaceuticals Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Takeda Pharmaceutical Company Limited

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Sanwa Kagaku Kenkyusho Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Towa Pharmaceutical Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Toa Eiyo Co., Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. AstraZeneca PLC

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Mochida Pharmaceutical Co., Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Lannett Company, Inc.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Horizon Therapeutics plc

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Sanofi S.A.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. GlaxoSmithKline plc

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Fuji Yakuhin Co., Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drugs for Treating Hyperuricemia Market

Figure 4: Global Drugs for Treating Hyperuricemia Market: Drivers

Figure 5: Global Drugs for Treating Hyperuricemia Market: Challenges

Figure 6: Global Drugs for Treating Hyperuricemia Market: Trends

Figure 7: Global Drugs for Treating Hyperuricemia Market: Opportunity

Figure 8: Global Drugs for Treating Hyperuricemia Market: Restraint

Figure 9: Global Drugs for Treating Hyperuricemia Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Drugs for Treating Hyperuricemia Market Value (USD Million) By Region

Figure 19: Global Drugs for Treating Hyperuricemia Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Drugs for Treating Hyperuricemia Market Value (USD Million) By Region

Figure 27: Global Drugs for Treating Hyperuricemia Market Share (%) By: Regions (2032)

Figure 28: Global Drugs for Treating Hyperuricemia Market Volume (K) By Region

Figure 29: Global Drugs for Treating Hyperuricemia Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Drugs for Treating Hyperuricemia Market Value (USD Million) By Region

Figure 37: Global Drugs for Treating Hyperuricemia Market Share (%) By: Regions (2032)

Figure 38: Global Drugs for Treating Hyperuricemia Market Volume (K) By Region

Figure 39: Global Drugs for Treating Hyperuricemia Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Drugs for Treating Hyperuricemia Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drugs for Treating Hyperuricemia Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Drugs for Treating Hyperuricemia Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Drugs for Treating Hyperuricemia Market Value (USD Million) By Region

Table 14: Global Drugs for Treating Hyperuricemia Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Drugs for Treating Hyperuricemia Market Volume (K) By Region

Table 31: Global Drugs for Treating Hyperuricemia Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Drugs for Treating Hyperuricemia Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Drugs for Treating Hyperuricemia Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Drugs for Treating Hyperuricemia Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 52: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 53: Mylan Pharmaceuticals Inc. Basic Information And Sales Area

Table 54: Mylan Pharmaceuticals Inc.. Products Portfolio

Table 55: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 56: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 57: Sanwa Kagaku Kenkyusho Co., Ltd. Basic Information And Sales Area

Table 58: Sanwa Kagaku Kenkyusho Co., Ltd.. Products Portfolio

Table 59: Towa Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 60: Towa Pharmaceutical Co., Ltd.. Products Portfolio

Table 61: Toa Eiyo Co., Ltd. Basic Information And Sales Area

Table 62: Toa Eiyo Co., Ltd.. Products Portfolio

Table 63: AstraZeneca PLC Basic Information And Sales Area

Table 64: AstraZeneca PLC. Products Portfolio

Table 65: Mochida Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 66: Mochida Pharmaceutical Co., Ltd.. Products Portfolio

Table 67: Lannett Company, Inc. Basic Information And Sales Area

Table 68: Lannett Company, Inc.. Products Portfolio

Table 69: Horizon Therapeutics plc Basic Information And Sales Area

Table 70: Horizon Therapeutics plc. Products Portfolio

Table 71: Sanofi S.A. Basic Information And Sales Area

Table 72: Sanofi S.A.. Products Portfolio

Table 73: GlaxoSmithKline plc Basic Information And Sales Area

Table 74: GlaxoSmithKline plc. Products Portfolio

Table 75: Fuji Yakuhin Co., Ltd. Basic Information And Sales Area

Table 76: Fuji Yakuhin Co., Ltd.. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Market Volume (K) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Types

Table 84: Global Market Share (%) By Types (2032)

Table 85: Global Drugs for Treating Hyperuricemia Market Value (USD Million) By Region

Table 86: Global Drugs for Treating Hyperuricemia Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Application

Table 89: North America Market Value (USD Million) (2025-2032) By Types

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Types

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Types

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 102: Global Drugs for Treating Hyperuricemia Market Volume (K) By Region

Table 103: Global Drugs for Treating Hyperuricemia Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Application

Table 106: North America Market Volume (K) (2025-2032) By Types

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Types

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Types

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Drugs for Treating Hyperuricemia Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	20.90 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Mylan Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Sanwa Kagaku Kenkyusho Co., Ltd.; Towa Pharmaceutical Co., Ltd.; Toa Eiyo Co., Ltd.; AstraZeneca PLC; Mochida Pharmaceutical Co., Ltd.; Lannett Company, Inc.; Horizon Therapeutics plc; Sanofi S.A.; GlaxoSmithKline plc; Fuji Yakuhin Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options